ENLV Research and Charts

ENLV - Enlivex Therapeutics Ltd (Healthcare: Biotechnology)

Projected Earnings Date: 2024-09-27 (Delayed quote data 2025-04-04)

Last 0.89	Change ⇓ -0.08 (0.00%)	Volume 104,011
	Open 0.92	High 0.93	Low 0.85

8EMA (Daily) 0.98	40EMA (Daily) 1.07	50EMA (Daily) 1.08	STO (Daily) 7.755	MACD Hist (Daily) -0.039
8EMA (Weekly) 1.060	40EMA (Weekly) 1.33	50EMA (Weekly) 1.44	STO (Weekly) 40.426	MACD Hist (Weekly) -0.001


Company Profile
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.